Vimian Group

41

SEK

-7.03 %

Less than 1K followers

VIMIAN

NASDAQ Stockholm

Health Care Providers

Health Care

Overview

Ownership

Investor consensus

-7.03%

+1.61%

+1.99%

+3.02%

-9.39%

+25.57%

-27.62%

-

-47.66%

Vimian Group is a group active in animal health. Through its subsidiaries, the company delivers medicines and technical solutions to veterinarians, laboratories, and pet owners. The products include, for example, drugs with associated clinical research and digital platforms for veterinary clinics. The company operates worldwide and is headquartered in Stockholm.

Market cap

21.48B SEK

Turnover

26.32M SEK

Revenue

4.3B

EBIT %

13.13 %

P/E

89.37

Dividend yield-%

-

Financial calendar

29.4

2025

General meeting '25

29.4

2025

Interim report Q1'25

18.7

2025

Interim report Q2'25

All

Webcasts

Press releases

ShowingAll content types

Regulatory press release3/28/2025, 7:30 AM

Notice of Annual General Meeting in Vimian Group AB (publ)

Regulatory press release3/28/2025, 6:30 AM

Trading in Vimian Group AB (publ)’s ordinary shares on Nasdaq Stockholm commences today

Regulatory press release3/21/2025, 10:15 AM

Vimian Group AB (publ) publishes prospectus in connection with its listing on Nasdaq Stockholm’s Main Market

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release3/19/2025, 7:00 AM

Vimian’s Nomination Committee proposes Pia Marions as new Board member

Regulatory press release3/14/2025, 2:35 PM

Vimian has been approved for listing on Nasdaq Stockholm

Regulatory press release3/14/2025, 7:00 AM

Vimian publishes Annual Report and Sustainability Report for 2024

Vimian Group, Audiocast with teleconference, Year-end Report, 2024

Webcast2/13/2025, 8:00 AM

Vimian Group, Audiocast with teleconference, Year-end Report, 2024

Regulatory press release2/13/2025, 6:45 AM

Vimian’s year-end report for 2024

Press release2/4/2025, 9:00 AM

Invitation to Vimian’s year-end report for 2024

Vimian Group, Audiocast with teleconference, Q3'24

Webcast10/24/2024, 7:00 AM

Vimian Group, Audiocast with teleconference, Q3'24

Regulatory press release10/24/2024, 5:45 AM

Vimian’s Interim Report for the third quarter of 2024

Press release10/18/2024, 8:00 AM

Invitation to Vimian’s Interim Report for the third quarter of 2024

Regulatory press release10/11/2024, 8:00 AM

Nomination Committee for Vimian’s 2025 Annual General Meeting

Regulatory press release9/6/2024, 6:04 AM

Vimian Group to enter new MedTech niche through the acquisition of a global veterinary dental company

Vimian Group, Audiocast with teleconference, Q2'24

Webcast8/15/2024, 7:00 AM

Vimian Group, Audiocast with teleconference, Q2'24

Regulatory press release8/15/2024, 5:45 AM

Vimian’s Interim Report for the second quarter of 2024

Press release8/6/2024, 8:00 AM

Invitation to Vimian’s Interim Report for the second quarter of 2024

Press release6/27/2024, 1:30 PM

Fidelio issues call options to Vimian’s Chairman of the Board Magnus Welander

Regulatory press release6/19/2024, 2:30 PM

Conversion of C-shares in Vimian Group AB

Regulatory press release6/11/2024, 6:00 AM

Vimian reaches settlement agreement with one of the main sellers of VOI in the previously announced indemnification process relating to the US patent dispute

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.